Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.

Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.

Veure altres versions (1)

OBJECTIVES: To compare the safety, reactogenicity, and immunogenicity of an adjuvanted split virion H1N1 vaccine and a non-adjuvanted whole virion vaccine used in the pandemic immunisation programme in the United Kingdom. DESIGN: Open label, randomised, parallel group, phase II study. SETTING: Five...

Descripció completa

Dades bibliogràfiques
Autors principals:	Waddington, C, Walker, W, Oeser, C, Reiner, A, John, T, Wilkins, S, Casey, M, Eccleston, P, Allen, R, Okike, I, Ladhani, S, Sheasby, E, Hoschler, K, Andrews, N, Waight, P, Collinson, A, Heath, P, Finn, A, Faust, SN, Snape, MD, Miller, E, Pollard, A
Format:	Journal article
Idioma:	English
Publicat:	2010

Ítems similars

Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines.
per: Andrews, N, et al.
Publicat: (2011)

Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines
per: Andrews, N, et al.
Publicat: (2011)

Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines
per: Andrews, N, et al.
Publicat: (2011)

Safety and immunogenicity of AS03 B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: Open label, randomised, parallel group, multicentre study
per: Waddington, C, et al.
Publicat: (2010)

Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03B/oil-in-water emulsion-adjuvanted (AS03B) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age
per: CS Waddington, et al.
Publicat: (2010-10-01)

Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age.
per: Waddington, C, et al.
Publicat: (2010)

Relationships between reactogenicity and age, dose number and immunogenicity in 937 children receiving two doses of ASO3(B)-adjuvanted split virion or whole virus H1N1 influenza A 2009 pandemic vaccines
per: Walker, W, et al.
Publicat: (2011)

H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: a multicenter follow-on study.
per: Walker, W, et al.
Publicat: (2012)

HIV-1 antibody--debris or virion?
per: Parren, P, et al.
Publicat: (1997)

Morphogenesis of the infectious HIV-1 virion
per: Jun-Ichi eSakuragi
Publicat: (2011-12-01)

Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later.
per: Hoschler, K, et al.
Publicat: (2014)

Future of flu vaccines. Expediting clinical trials in a pandemic.
per: Pollard, A, et al.
Publicat: (2009)

Future of flu vaccines. Expediting clinical trials in a pandemic.
per: Pollard, A, et al.
Publicat: (2009)

Mechanism of HIV-1 virion entrapment by tetherin.
per: Siddarth Venkatesh, et al.
Publicat: (2013-01-01)

Hydroxyapatite chromatography of phage-display virions
per: George P. Smith, et al.
Publicat: (2005-12-01)

RF_phage virion: Classification of phage virion proteins with a random forest model
per: Yanqin Zhang, et al.
Publicat: (2023-02-01)

Enhanced immunogenicity, mortality protection, and reduced viral brain invasion by alum adjuvant with an H5N1 split-virion vaccine in the ferret.
per: Robert Colby Layton, et al.
Publicat: (2011-01-01)

AS03-adjuvanted H7N9 inactivated split virion vaccines induce cross-reactive and protective responses in ferrets
per: Daniel Stadlbauer, et al.
Publicat: (2021-03-01)

Human memory T cell dynamics after aluminum-adjuvanted inactivated whole-virion SARS-CoV-2 vaccination
per: Ece Tavukcuoglu, et al.
Publicat: (2023-03-01)

Structure and Assembly of TP901-1 Virion Unveiled by Mutagenesis.
per: Stephen R Stockdale, et al.
Publicat: (2015-01-01)

COVID-19: The biology behind the virion
per: V Vasanthi, et al.
Publicat: (2020-01-01)

Native morphology of influenza virions
per: Takeshi eNoda
Publicat: (2012-01-01)

Purification of Herpesvirus Virions and Capsids
per: Xinghong Dai, et al.
Publicat: (2014-08-01)

Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals.
per: Heimo Lagler, et al.
Publicat: (2012-01-01)

Corrigendum: RF_phage virion: classification of phage virion proteins with a random forest model
per: Yanqin Zhang, et al.
Publicat: (2023-06-01)

IQGAP1 Negatively Regulates HIV-1 Gag Trafficking and Virion Production
per: Yosef Sabo, et al.
Publicat: (2020-03-01)

Antibody persistence and booster responses to Split-Virion H5N1 avian Influenza vaccine in young and elderly adults
per: Lazarus, R, et al.
Publicat: (2016)

Safety and immunogenicity of a split-virion AS03A-adjuvanted A/Indonesia/05/2005 (H5N1) vaccine in Taiwanese adults
per: Pan-Chyr Yang, et al.
Publicat: (2012-06-01)

Superinfection Exclusion of Alphaherpesviruses Interferes with Virion Trafficking
per: James P. Cwick, et al.
Publicat: (2022-06-01)

APOBEC3G encapsidation into HIV-1 virions: which RNA is it?
per: Khan Mohammad A, et al.
Publicat: (2008-07-01)

A Reduced Dose Whole Virion Aluminum Adjuvanted Seasonal Influenza Vaccine Is Immunogenic, Safe, and Well Tolerated in Pediatric Patients
per: Zoltan Vajo, et al.
Publicat: (2021-03-01)

Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults.
per: Leroux-Roels, I, et al.
Publicat: (2009)

Deep-learning in situ classification of HIV-1 virion morphology
per: Juan S. Rey, et al.
Publicat: (2021-01-01)

HIV-1 antibody - Debris or virion? (vol 3, pg 366, 1997)
per: Parren, P, et al.
Publicat: (1997)

Proteomic analysis of the EhV-86 virion
per: Lilley Kathryn S, et al.
Publicat: (2008-03-01)

Palisade structure in intact vaccinia virions
per: Miguel Hernandez-Gonzalez, et al.
Publicat: (2024-02-01)

Structural Heterogeneity of the Rabies Virus Virion
per: Xiaoying Cai, et al.
Publicat: (2024-09-01)

On the Sensitivity of the Virion Envelope to Lipid Peroxidation
per: Consuelo B. Correa Sierra, et al.
Publicat: (2022-10-01)

Packaging of viral RNAs in virions of adenoviruses
per: Xing Li, et al.
Publicat: (2009-02-01)

Properties of virion transactivator proteins encoded by primate cytomegaloviruses
per: Barry Peter A, et al.
Publicat: (2009-05-01)